FDA approved Gilead Sciences Inc.’s HIV drug Truvada (emtricitabine/tenofovir) for pre-exposure prophylaxis (PrEP) with stronger label warnings and directions for use than originally proposed, but without a restricted distribution system that had been urged by some of the agency’s outside experts.
On July 16, FDA approved the nucleoside/nucleotide reverse transcriptase inhibitor, in combination with safer sex practices, for PrEP to reduce...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?